Decoy Therapeutics CBO Peter Marschel Receives 3,900-Share Award

What Happened

• Peter Klaus Marschel, Chief Business Officer of Decoy Therapeutics Inc., was granted 3,900 restricted shares on 2026-08-31. The shares were reported at $0.00 per share (no cash paid) under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan.
• This was an equity award (code A). The filing reports the grant amount but does not state a cash value on the Form 4.

Key Details

• Transaction date: 2026-08-31; Form 4 filed 2026-09-02 (timely filing).
• Award: 3,900 restricted common shares granted at $0.00 per share.
• Vesting: 25% of the restricted stock vested immediately; the remaining 75% vests in approximately equal monthly increments over the next 36 months (per footnote).
• Plan: Grant made under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan.
• Shares owned after transaction: Not specified in the filing.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax withholding, or sale noted in this filing.

Context

• Restricted stock awards are a form of compensation that align an executive’s interests with shareholders because the recipient must typically meet vesting conditions to fully own the shares. This grant does not represent an open-market purchase or sale and should be interpreted as a compensation-related issuance rather than a direct buy/sell signal.